Cemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 >= 50%
Göster/ Aç
Tarih
2019Yazar
Sezer, A.
Gogishvili, M.
Bentsion, D.
Kilickap, S.
Lowczak, A.
Gumus, M.
Gladkow, O.
Clingan, P.
Sriuranpong, V.
Rizvi, N.
Lee, S.
Li, S.
Snodgrass, P.
Navarro, M.
Lowy, I.
Rietschel, P.